KURA ONCOLOGY DL-,0001 WKN: A143UH ISIN: US50127T1097 Kürzel: KUR Forum: Aktien Thema: Hauptdiskussion

https://seekingalpha.com/article/4394095-kura-oncology-advanced-precision-medicine-opportunity-excites-not-without-risks

Kura Oncology Announces Pricing of $300 Million Public Offering of Common Stock https://www.globenewswire.com/news-release/2020/12/09/2141845/0/en/Kura-Oncology-Announces-Pricing-of-300-Million-Public-Offering-of-Common-Stock.html ...at a price to the public of $37.00 per share. 

Kura Oncology Announces Commencement of Public Offering of Common Stock https://www.globenewswire.com/news-release/2020/12/07/2140893/0/en/Kura-Oncology-Announces-Commencement-of-Public-Offering-of-Common-Stock.html

https://seekingalpha.com/news/3642222-kura-oncology-sized-up-favorably-for-long-term-after-ash-presentation

https://seekingalpha.com/news/3642092-kura-oncology-jumps-16-after-announcing-first-in-human-data-for-aml-candidate Kura Oncology Jumps 16% After Announcing First In-Human Data for AML Candidate

🍀

Kura Oncology Reports Third Quarter 2020 Financial Results https://www.globenewswire.com/news-release/2020/11/05/2120945/0/en/Kura-Oncology-Reports-Third-Quarter-2020-Financial-Results.html – Preliminary data from first-in-human trial of menin inhibitor KO-539 accepted for oral presentation at ASH – – Encouraging safety, tolerability and activity with KO-539 highlighted in ASH abstract – – Preclinical data support expansion opportunity for tipifarnib plus PI3Kα inhibitor in HRAS- and/or PI3K-dependent tumors – – $325.4 million in cash, cash equivalents and investments provide runway into 2023 – ...

https://www.globenewswire.com/news-release/2020/10/07/2104839/0/en/Kura-Oncology-Announces-Preliminary-Data-for-Menin-Inhibitor-KO-539-Accepted-for-Oral-Presentation-at-ASH.html Kura Oncology Announces Preliminary Data for Menin Inhibitor KO-539 Accepted for Oral Presentation at ASH – First clinical data from the KOMET-001 study to be presented on December 5, 2020 –

.

👀

Phase 2 und solche Auswirkungen? Hätte auch gerne bei Array so sein können

KURA has positive topline results from a Phase 2 trial for its lead product candidate, tipifarnib, in patients with HRAS mutant relapsed or refractory squamous cell carcinomas of the head and neck (HNSCC).

Habe mittlerweile fast +17% und werde gleich aussteigen..mal sehen! Habe die News frühzeitig gelesen aber lange gezögert.. Es ist nur Phase 2

Bist du etwa investiert Abu Say?

Krass!!